Trials / Completed
CompletedNCT02794636
Interferon Toxicities in Melanoma Treatment
Analysis of the Clinical and Economic Impact of Adverse Events and Medication-related Toxicities Associated With Interferon (IFN) Treatment for Patients With Stage III Melanoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 436 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting. A secondary objective is to quantify annual costs and resource utilization before and after IFN initiation among patients with stage III melanoma in a real-world setting.
Conditions
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2016-06-09
- Last updated
- 2016-06-09
Source: ClinicalTrials.gov record NCT02794636. Inclusion in this directory is not an endorsement.